| DB ID | MyCo_1526 |
| Title | Is there an interest in systematic serum screening for aspergillosis in COVID-19 patients in a medical ward? |
| Year | 2024 |
| PMID | 38636842 |
| Fungal Diseases involved | Bronchopulmonary aspergillosis |
| Associated Medical Condition | COVID-19 patients |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study was approved by the local ethics committee (number CE-2020–51). |
| Site of Infection | Lungs |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | In the wake of an emerging CAPA crisis, in October 2020 we decided, following a local consensus, to expand the systematic serum aspergillosis screening customarily performed in ICUs to other medical wards receiving all COVID-19 patients. Thirty patients (median age =66.5 years [range: 27–90 years]; 63 % males) were included between October 1, 2020 and October 31, 2020; since no cases of COVID-19-associated aspergillosis were detected during this period, the screening was stopped. |
| Cohort No. | 30 |
| Age Group | 27-90 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | COVID-19-associated pulmonary aspergillosis (CAPA) is observed in 5 %–15 % of severe COVID-19 cases and is associated with significantly amplified mortality rates (44 %). In April 2020, several articles suggested systematic serum screening for aspergillosis in ICU COVID-19 patients. At that time, sensitivity testing for respiratory samples combining culture, biopsy, and galactomannan antigen (GM) testing in bronchoalveolar lavage (BAL) and serum 1,3-ß-D-glucan (BDG) and GM appeared optimal. More recently, Aspergillus fumigatus polymerase chain reaction (PCR) testing has been carried out for the purposes of diagnosing CAPA. |
| Technique | Assay |
| Analysis Method | ELISA Based |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad Laboratories, Hungary) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | BDG-Fungitell Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
